Tumor vaccination technology has been developed for patients with malignant brain tumors. The efficacy of such therapeutic vaccines was demonstrated by the extension of patient survival.

There are evidences that immuno-therapeutic strategies may also extend survival time in patients with kidney, pancreas, or uterine cancers.

To propose this therapy for patients with kidney, pancreas or uterine cancers in the University Hospital Leuven, an immunotherapeutic platform has been created that will be conducted by the team of Professor Van Gool.

This team has accumulated deep knowledge in dedicated pre-clinical research with cells, cell lines, and mouse models.
The team possesses the particular expertise to prepare therapeutic vaccines in a Good Manufacturing Practice facility in compliance with the state of the art regulations. The involved oncologists bring patients from their respective domain into the immuno-therapeutic platform, following the inclusion criteria, and they can exchange experience and results with the other groups inside the platform.
By doing so, the therapeutic vaccines for the different oncologic domains are produced by one and the same experienced team.
Knowledge and expertise grow together but remain accessible for a large and varied patient group.

Our organization allows the direct transfer of innovative immuno-modulations of the vaccine therapy from pre-clinical research to the respective oncologic complaints.

It represents a unique but achievable model to afford each patient a tailored innovative therapy developed from our own academic scientific research, with the aim to prolong patient survival in a good quality of life.